Current treatment strategies for inhibiting mTOR in cancer (Articolo in rivista)

Type

• Articolo in rivista (Classe)
• Prodotto della ricerca (Classe)

Label

• Current treatment strategies for inhibiting mTOR in cancer (Articolo in rivista) (literal)

Anno

• 2015-01-01T00:00:00+01:00 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#doi

• 10.1016/j.tips.2014.11.004 (literal)

Alternative label

• Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. (2015)
  Current treatment strategies for inhibiting mTOR in cancer
  in Trends in pharmacological sciences (Regular ed., Print)
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Chiarini F, Evangelisti C, McCubrey JA, Martelli AM. (literal)

Pagina inizio

• 124 (literal)

Pagina fine

• 135 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#url

• http://www.scopus.com/inward/record.url?eid=2-s2.0-84915745554&partnerID=q2rCbXpz (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 36 (literal)

Rivista

• Trends in pharmacological sciences (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo

• 2 (literal)

Note

• Scopu (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• Institute of Molecular Genetics, National Research Council, Bologna, Italy; Rizzoli Orthopedic Institute, Bologna, Italy; Department of Microbiology and Immunology, Brody School of Medicine, East Carolina University, Greenville, NC, USA; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy (literal)

Titolo

• Current treatment strategies for inhibiting mTOR in cancer (literal)

Abstract

• Mammalian target of rapamycin (mTOR) is a Ser/Thr kinase that regulates a wide range of functions, including cell growth, proliferation, survival, autophagy, metabolism, and cytoskeletal organization. mTOR activity is dysregulated in several human disorders, including cancer. The crucial role of mTOR in cancer cell biology has stimulated interest in mTOR inhibitors, placing mTOR on the radar of the pharmaceutical industry. Several mTOR inhibitors have already undergone clinical trials for treating tumors, without great success, although mTOR inhibitors are approved for the treatment of some types of cancer, including advanced renal cell carcinoma. However, the role of mTOR inhibitors in cancer treatment continues to evolve as new compounds are continuously being disclosed. Here we review the three classes of mTOR inhibitors currently available for treating cancer patients. Moreover, we highlight efforts to identify markers of resistance and sensitivity to mTOR inhibition that could prove useful in the emerging field of personalized medicine. (literal)

Prodotto di

• Institute of molecular genetics (IGM) (Istituto)
• Bersagli molecolari per il controllo della progressione tumorale (ME.P03.012.001) (Modulo)

Autore CNR

• CAMILLA EVANGELISTI (Persona)
• FRANCESCA CHIARINI (Unità di personale interno)

Insieme di parole chiave

• Parole chiave di "Current treatment strategies for inhibiting mTOR in cancer" (Insieme di parole chiave)

Incoming links:

Prodotto

• Institute of molecular genetics (IGM) (Istituto)
• Bersagli molecolari per il controllo della progressione tumorale (ME.P03.012.001) (Modulo)

Autore CNR di

• FRANCESCA CHIARINI (Unità di personale interno)
• CAMILLA EVANGELISTI (Persona)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi

• Trends in pharmacological sciences (Rivista)

Insieme di parole chiave di

• Parole chiave di "Current treatment strategies for inhibiting mTOR in cancer" (Insieme di parole chiave)